The present invention relates to 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]- [1,2,4]triazolo[1,5-a]pyrazine hemiadipate, which is non-hygroscopic. The present invention also relates to pharmaceutical compositions comprising 5,8-Dimethyl-2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)- ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate, as well as the use of 5,8-Dimethyl-2-[2-(1-methyl-4- phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate in therapy. The 5,8-Dimethyl- 2-[2-(1-methyl-4-phenyl-1H-imidazol-2-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyrazine hemiadipate being depicted below. Formula (I).La présente invention concerne un hémiadipate de 5,8-diméthyl-2-[2-(1-méthyl-4-phényl-1H-imidazol-2-yl)-éthyl]- [1,2,4]triazolo[1,5-a]pyrazine, qui est non hygroscopique. La présente invention concerne également des compositions pharmaceutiques comprenant l'hémiadipate de 5,8-diméthyl-2-[2-(1-méthyl-4-phényl-1H-imidazol-2-yl)- éthyl]-[1,2,4]triazolo[1,5-a]pyrazine, ainsi que l'utilisation de l'hémiadipate de 5,8-diméthyl-2-[2-(1-méthyl-4- phényl-1H-imidazol-2-yl)-éthyl]-[1,2,4]triazolo[1,5-a]pyrazine en thérapie. L'hémiadipate de 5,8-diméthyl- 2-[2-(1-méthyl-4-phényl-1H-imidazol-2-yl)-éthyl]-[1,2,4]triazolo[1,5-a]pyrazine étant représenté ci-dessous. Formule (I).
